Literature DB >> 27561762

Outcomes of Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

Nadia R Sutton1, Milan Seth1, Cyril Ruwende2, Hitinder S Gurm3.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is increasing in prevalence, and patients with a history of AF commonly undergo percutaneous coronary intervention (PCI). There is a paucity of contemporary data on the association between AF and clinical outcomes after PCI.
OBJECTIVES: The study sought to evaluate the association between AF and in-hospital adverse outcomes using a large, prospective multicenter registry.
METHODS: Data for consecutive PCI cases from 47 hospitals performed between April 2011 and December 2014 were utilized for the analysis. Propensity-matched multivariate analysis was used to adjust for differences in baseline characteristics between patients with and without a history of AF.
RESULTS: Of 113,283 PCI cases during the study period, a history of AF was present in 13,912 patients (12%), which varied by institution (range 2.5% to 18.4%). At baseline, patients with a history of AF were older and were more likely to have comorbid congestive heart failure, cardiomyopathy, cerebrovascular disease, and chronic lung disease. Patients with a history of AF were more likely to have in-hospital complications, including in-hospital mortality (3% vs. 1%). In propensity-matched analysis, patients with a history of AF were more likely to be treated with a bare-metal stent (27% vs. 18%). In the propensity-matched model, AF remained independently associated with an increased risk of developing post-procedural bleeding (odds ratio [OR]: 1.32; 95% confidence interval [CI]: 1.15 to 1.52), heart failure (OR: 1.33; 95% CI: 1.17 to 1.52), cardiogenic shock (OR: 1.26; 95% CI: 1.08 to 1.48), and in-hospital mortality (OR: 1.41; 95% CI: 1.18 to 1.68).
CONCLUSIONS: AF is common among patients undergoing PCI. AF is associated with older age, the presence of other comorbidities, and independently associated with in-hospital post-procedural heart failure, cardiogenic shock, and mortality.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute coronary syndrome; clinical outcomes; stable angina

Mesh:

Year:  2016        PMID: 27561762     DOI: 10.1016/j.jacc.2016.05.085

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  24 in total

1.  Outcomes of patients with periprocedural atrial fibrillation undergoing percutaneous coronary intervention for chronic total occlusion.

Authors:  Barbara E Stähli; Cathérine Gebhard; Michael Gick; Kambis Mashayekhi; Miroslaw Ferenc; Heinz Joachim Buettner; Franz-Josef Neumann; Aurel Toma
Journal:  Clin Res Cardiol       Date:  2017-08-03       Impact factor: 5.460

2.  Exploring the Healthcare Value of Percutaneous Coronary Intervention: Appropriateness, Outcomes, and Costs in Michigan Hospitals.

Authors:  Daniel M Alyesh; Milan Seth; David C Miller; James M Dupree; John Syrjamaki; Devraj Sukul; Simon Dixon; Eve A Kerr; Hitinder S Gurm; Brahmajee K Nallamothu
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-06

Review 3.  Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble.

Authors:  Massimo Leggio; Augusto Fusco; Paolo Severi; Mario Lombardi; Elisa Caldarone; Stefania D'Emidio; Massimo Armeni; Daniela Mereu; Maria Grazia Bendini; Andrea Mazza
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

4.  Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation.

Authors:  Serkan Cay; Meryem Kara; Firat Ozcan; Ozcan Ozeke; Tolga Aksu; Dursun Aras; Serkan Topaloglu
Journal:  J Interv Card Electrophysiol       Date:  2022-04-02       Impact factor: 1.900

5.  Association of Timing of Aortic Valve Replacement Surgery After Stroke With Risk of Recurrent Stroke and Mortality.

Authors:  Charlotte Andreasen; Mads Emil Jørgensen; Gunnar H Gislason; Andreas Martinsson; Robert D Sanders; Jawdat Abdulla; Per Føge Jensen; Christian Torp-Pedersen; Lars Køber; Charlotte Andersson
Journal:  JAMA Cardiol       Date:  2018-06-01       Impact factor: 14.676

6.  The Impact of Atrial Fibrillation on In-Hospital Outcomes in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Coronary Revascularization with Percutaneous Ventricular Assist Device Support.

Authors:  Gupta Sonu; Desai Rupak; Hanna Bishoy; Deshmukh Abhishek; Kumar Gautam; Sachdeva Rajesh; E Berman Adam
Journal:  J Atr Fibrillation       Date:  2020-02-28

7.  Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting.

Authors:  Heng-Bo Zhai; Jun Liu; Zhi-Chao Dong; Dong-Xia Wang; Bo Zhang
Journal:  Chin Med J (Engl)       Date:  2017-06-20       Impact factor: 2.628

8.  Applying the CHA2DS2-VASc score to predict the risk of future acute coronary syndrome in patients receiving catheter ablation for atrial fibrillation.

Authors:  Ching-Yao Chou; Yun-Yu Chen; Yenn-Jiang Lin; Kuo-Liong Chien; Shih-Lin Chang; Ta-Chuan Tuan; Li-Wei Lo; Tze-Fan Chao; Yu-Feng Hu; Fa-Po Chung; Jo-Nan Liao; Chin-Yu Lin; Ting-Yung Chang; Shih-Ann Chen
Journal:  Int J Cardiol Heart Vasc       Date:  2020-06-28

9.  Effect of atrial fibrillation in Asian patients undergoing percutaneous coronary intervention with drug-eluting stents for stable coronary artery disease: Results from a Korean nationwide study.

Authors:  Seungbong Han; Gyung-Min Park; Yong-Giun Kim; Ki Won Hwang; Jae-Hyung Roh; Ki-Bum Won; Soe Hee Ann; Shin-Jae Kim; Sang-Gon Lee
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

Review 10.  Antithrombotic therapy strategies for atrial fibrillation patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis.

Authors:  Xiaoxuan Gong; Shaowen Tang; Jiangjin Li; Xiwen Zhang; Xiaoyi Tian; Shuren Ma
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.